CompletedNot Applicable

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Japan50 participantsStarted 2019-12-26

Plain-language summary

This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.

Who can participate

Age range12 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic Hepatitis C Virus (HCV) infection treated in daily practice with Maviret * Enrolled after Maviret treatment begins * Prior treatment with Maviret Exclusion Criteria: None

What they're measuring

Number of Participants with Adverse Drug Reactions (ADRs)

Timeframe: Up to approximately 36 weeks

Percentage of Participants with Adverse Drug Reactions (ADRs)

Timeframe: Up to approximately 36 weeks

Number of Participants with Serious Adverse Events (SAEs)

Timeframe: Up to approximately 36 weeks

Percentage of Participants with Serious Adverse Events (SAEs)

Timeframe: Up to approximately 36 weeks

Trial details

NCT IDNCT04214028

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-08-01

View on ClinicalTrials.gov More Hepatitis C Virus (HCV) trials